GO:0070697 activin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070697 (activin receptor binding) is a molecular function defined as binding to an activin receptor, a key event in TGF-beta superfamily signaling.
• Activin receptors are serine/threonine kinases that mediate signaling by activin, myostatin, and related ligands, regulating muscle growth, metabolism, and development.
• The extracellular ligand-binding domain of type II activin receptors adopts a three-finger toxin fold, a unique structural feature for ligand recognition.
• Blocking activin receptor binding with antibodies or natural inhibitors like DLK1 can induce muscle hypertrophy and protect against atrophy, highlighting therapeutic potential.
• Dysregulated activin receptor binding is implicated in obesity, muscle wasting, and cancer cachexia, making it a target for drug development.
• CRISPR-based models (knockout, knock-in, overexpression) are essential to dissect the causal roles of activin receptor binding in health and disease.
Description
Activin receptor binding (GO:0070697) is a molecular function that describes the physical interaction between a ligand and an activin receptor, a subclass of the transforming growth factor beta (TGF-beta) superfamily of receptors. This binding event is the first step in a signaling cascade that controls diverse cellular processes, including cell growth, differentiation, and apoptosis. Activin receptors are serine/threonine kinases, and their activation by ligands such as activin, myostatin, and GDF11 triggers phosphorylation of downstream SMAD proteins, leading to transcriptional changes. Researchers study this term to understand how extracellular cues are translated into intracellular responses, and to develop therapies for conditions like muscle wasting, obesity, and cancer. The specificity of ligand-receptor interactions is critical; for example, activin E signals specifically through activin receptor-like kinase 7 (ALK7), while other ligands may activate ALK4 or ALK5. Structural studies have revealed that the extracellular domain of type II activin receptors adopts a three-finger toxin fold, which is essential for high-affinity ligand binding. This article explores the mechanisms, key genes, and research methods associated with activin receptor binding, providing a comprehensive resource for biomedical researchers.
activin receptor binding At A Glance
| GO ID | GO:0070697 |
|---|---|
| GO term | activin receptor binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to an activin receptor, initiating TGF-beta superfamily signaling |
| Related ligands | Activin A, activin B, activin E, myostatin, GDF11, DLK1 |
| Related receptors | ACVR1B (ALK4), ACVR1C (ALK7), ACVR2A, ACVR2B |
| Structural feature | Extracellular ligand-binding domain with three-finger toxin fold |
| Therapeutic relevance | Target for muscle hypertrophy, obesity, and cancer cachexia |
What Is GO:0070697?
According to the Gene Ontology, GO:0070697 (activin receptor binding) is defined as the binding to an activin receptor. In other words, it is the molecular function of a protein or ligand physically interacting with an activin receptor, which is a transmembrane serine/threonine kinase receptor. This binding typically occurs via the extracellular domain of the receptor and can lead to receptor activation and downstream signaling.
Why Is activin receptor binding Important in Cell Biology?
Activin receptor binding is a critical molecular event that governs the activity of the TGF-beta superfamily, which regulates a wide array of physiological processes including embryonic development, tissue homeostasis, and immune function. Dysregulation of this binding is associated with numerous pathologies, such as skeletal muscle atrophy, obesity, fibrosis, and cancer. Understanding the precise molecular interactions involved in activin receptor binding can inform the design of therapeutic agents, such as monoclonal antibodies and small molecule inhibitors, that modulate this pathway. Moreover, the discovery of natural inhibitors like DLK1 provides insights into endogenous regulatory mechanisms. Therefore, research on GO:0070697 is essential for both basic biology and translational medicine.
• Regulates skeletal muscle growth and hypertrophy; blockade of activin receptor binding leads to muscle mass increase.
• Involved in metabolic control, including obesity and insulin resistance; activin E signals through ALK7 to affect metabolism.
• Plays a role in cancer cachexia and muscle wasting, making it a therapeutic target.
• Mediates signaling by myostatin, a negative regulator of muscle growth.
• DLK1 acts as an endogenous inhibitor of activin receptor binding, highlighting regulatory mechanisms.
• Small molecule inhibitors like SB-431542 block activin receptor kinases, affecting binding and downstream signaling.
• Structural insights into the ligand-binding domain aid in rational drug design.
• Activin receptor binding is essential for developmental processes such as mesoderm induction and left-right asymmetry.
• Dysregulation is linked to fibrosis and cancer progression.
• CRISPR screening can identify novel modulators of activin receptor binding.
Molecular Mechanism of activin receptor binding
Ligand Recognition and Binding
In simple terms: This is the first step where a ligand molecule docks onto the activin receptor.
Activin receptor binding begins with the specific recognition of a ligand, such as activin A, myostatin, or activin E, by the extracellular domain of the receptor. The type II receptor (ACVR2A or ACVR2B) binds the ligand with high affinity, and this interaction is structurally characterized by a three-finger toxin fold in the receptor's ligand-binding domain. This binding is essential for recruiting and activating type I receptors (e.g., ALK4, ALK5, ALK7).
Receptor Complex Assembly and Activation
In simple terms: After the ligand binds, the receptor brings in a partner receptor to form an active complex.
Upon ligand binding, the type II receptor forms a complex with a type I receptor, leading to phosphorylation of the type I receptor by the type II kinase. This phosphorylation activates the type I receptor kinase, which then phosphorylates downstream SMAD proteins (SMAD2/3). The specificity of this assembly is determined by the ligand and the receptor subtypes; for example, activin E specifically signals through ALK7.
Regulation by Endogenous Inhibitors
In simple terms: Some proteins can block the binding to control the signal.
Endogenous proteins such as DLK1 can inhibit activin receptor binding by interacting with the receptor or ligand, thereby preventing downstream signaling. This regulation is crucial for fine-tuning TGF-beta superfamily activity in processes like muscle regeneration and metabolism.
Pharmacological Modulation
In simple terms: Drugs can interfere with the binding to treat diseases.
Monoclonal antibodies against activin type II receptors (e.g., bimagrumab) block ligand binding and induce muscle hypertrophy. Small molecule inhibitors like SB-431542 target the kinase activity of type I receptors, indirectly affecting binding-mediated signaling. Dual anti-ActRIIA/IIB antibodies have shown maximal effects on muscle growth.
Key Genes Involved in GO:0070697 activin receptor binding
The following genes encode proteins that are directly involved in activin receptor binding or its regulation, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACVR2A | Type II activin receptor; binds activin and myostatin | Target for muscle hypertrophy; antibody blockade |
| ACVR2B | Type II activin receptor; binds activin and myostatin | Target for muscle hypertrophy; dual blockade |
| ACVR1B | Type I receptor (ALK4); mediates activin signaling | Inhibited by SB-431542; involved in fibrosis |
| ACVR1C | Type I receptor (ALK7); mediates activin E signaling | Metabolic regulation; obesity target |
| INHBA | Activin beta A subunit; forms activin A | Ligand for activin receptors; regulates muscle |
| INHBB | Activin beta B subunit; forms activin B | Ligand for activin receptors |
| INHBE | Activin beta E subunit; forms activin E | Signals through ALK7; metabolic roles |
| MSTN | Myostatin; negative regulator of muscle growth | Ligand for ACVR2B; muscle atrophy target |
| GDF11 | Growth differentiation factor 11; related ligand | Binds activin receptors; aging and muscle |
| DLK1 | Endogenous inhibitor of activin receptor binding | Regulates muscle and metabolism |
| SMAD2 | Downstream effector of activin signaling | Phosphorylated upon receptor activation |
| SMAD3 | Downstream effector of activin signaling | Phosphorylated upon receptor activation |
| FKBP12 | Binds type I receptors; regulates signaling | Modulates activin receptor activity |
| BAMBI | Pseudo-receptor; inhibits TGF-beta signaling | Negative regulator of activin receptor binding |
| SB-431542 | Small molecule inhibitor of ALK4/5/7 | Tool compound for studying activin signaling |
| Bimagrumab | Monoclonal antibody against ActRIIA/IIB | Clinical trials for obesity and muscle wasting |
How Is activin receptor binding Regulated?
Activin receptor binding is regulated at multiple levels. Endogenous inhibitors such as DLK1 can directly bind to the receptor or ligand to prevent signaling. Additionally, decoy receptors like BAMBI can sequester ligands or interfere with receptor complex formation. Intracellularly, FKBP12 binds to type I receptors and stabilizes them in an inactive conformation, preventing leaky signaling. Phosphorylation of the type I receptor by the type II receptor is a key activation step that is tightly controlled. Pharmacological agents, including small molecule inhibitors (e.g., SB-431542) and monoclonal antibodies (e.g., bimagrumab), can modulate binding and downstream effects. These regulatory mechanisms ensure proper spatial and temporal control of activin signaling.
activin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACVR2B | Muscle atrophy, cachexia | KO mice, antibody treatment |
| ACVR1C | Obesity, insulin resistance | KO mice, ALK7 inhibitors |
| MSTN | Muscle hypertrophy, dystrophy | Overexpression, KO |
| DLK1 | Metabolic disorders, muscle regeneration | KO, overexpression |
| INHBE | Metabolic syndrome | KO, point mutation |
Muscle Wasting and Sarcopenia
Dysregulation of activin receptor binding contributes to muscle atrophy and sarcopenia. Blocking the interaction between myostatin and activin type II receptors with antibodies induces muscle hypertrophy and protects against atrophy in preclinical models. Bimagrumab, an anti-ActRII antibody, is being investigated for obesity and muscle wasting. These findings highlight the therapeutic potential of targeting activin receptor binding to enhance muscle mass.
Obesity and Metabolic Disorders
Activin E signals specifically through ALK7 (ACVR1C) and has been implicated in metabolic regulation. Bimagrumab treatment has shown effects on fat mass reduction in clinical trials, suggesting that activin receptor binding plays a role in adipose tissue homeostasis. Thus, modulating this pathway may offer new strategies for treating obesity and related metabolic syndromes.
Cancer and Cachexia
Activin signaling is involved in cancer cachexia, a condition characterized by severe muscle and fat loss. Antibodies blocking activin type II receptors have been shown to ameliorate cachexia in tumor-bearing models. Additionally, small molecule inhibitors of activin receptor kinases like SB-431542 are being explored for their anti-tumor effects. Therefore, activin receptor binding is a promising target for cancer-associated wasting.
From activin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of ACVR2B increase muscle mass? | ACVR2B KO mouse or CRISPR KO in C2C12 cells |
| What is the effect of a point mutation in ACVR1C on ligand binding? | CRISPR point mutation knock-in in HEK293 cells |
| Can overexpression of DLK1 inhibit activin signaling? | DLK1 overexpression in muscle cells |
| How does tagged ACVR2A localize in cells? | Knock-in of fluorescent tag at ACVR2A locus |
| What genes modulate activin receptor binding? | CRISPR library screening in reporter cells |
| Does bimagrumab affect muscle hypertrophy? | Mouse models treated with antibody |
How to Study the activin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics | Ligand-receptor interaction studies |
| X-ray crystallography | 3D structure of protein complexes | Structural basis of binding |
| Luciferase reporter assay | Transcriptional activity of SMADs | Screening for inhibitors |
| Western blot | Phosphorylation of SMAD2/3 | Pathway activation |
| CRISPR knockout screen | Gene essentiality for signaling | Identifying novel regulators |
| Immunoprecipitation | Protein-protein interactions | Detecting receptor complexes |
| Flow cytometry | Cell surface receptor expression | Quantifying binding sites |
Binding Assays
Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) can measure the affinity and kinetics of ligand binding to activin receptors. These methods provide quantitative data on binding constants and are essential for understanding molecular interactions.
Structural Biology
X-ray crystallography and cryo-electron microscopy have been used to solve the structure of the extracellular domain of type II activin receptors, revealing the three-finger toxin fold. These structural insights guide the design of inhibitors and antibodies.
Cell-Based Signaling Assays
Luciferase reporter assays (e.g., SMAD-responsive reporters) are commonly used to measure activin receptor signaling activity after ligand stimulation or inhibitor treatment. Phosphorylation of SMAD2/3 can be detected by Western blot to assess pathway activation.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify genes that regulate activin receptor binding and downstream signaling. These screens are powerful for discovering novel modulators and therapeutic targets.
How CRISPR Can Be Used to Study GO:0070697 activin receptor binding
Knockout
CRISPR knockout of activin receptor genes (e.g., ACVR2A, ACVR2B, ACVR1C) in cell lines or animal models can abolish ligand binding and downstream signaling, providing causal insights into their roles in muscle growth, metabolism, and disease. For example, ACVR2B knockout mice exhibit muscle hypertrophy.
Point Mutation
Introducing point mutations in the ligand-binding domain of activin receptors via CRISPR can dissect the specific residues required for ligand interaction. Such models help validate structural predictions and identify critical binding determinants.
Knock-in
Knock-in of epitope tags or fluorescent proteins at endogenous activin receptor loci allows real-time imaging and biochemical analysis of receptor trafficking and complex formation. This approach preserves native regulation and expression levels.
Overexpression
CRISPR activation (CRISPRa) or traditional overexpression of activin receptors or their ligands can amplify signaling and reveal gain-of-function phenotypes, such as enhanced muscle growth or metabolic changes. Overexpression of DLK1, an inhibitor, can suppress activin signaling.
How EDITGENE Supports activin receptor binding Research
Researchers studying activin receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor activation, or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to create precise cellular and animal models, enabling rigorous functional studies.
Contact EDITGENE today to design your custom CRISPR model for activin receptor binding research.
Frequently Asked Questions About activin receptor binding
What is activin receptor binding?
Activin receptor binding (GO:0070697) is the molecular function of a protein or ligand physically interacting with an activin receptor, a key step in TGF-beta superfamily signaling.
What genes are involved in activin receptor binding?
Key genes include ACVR2A, ACVR2B, ACVR1B, ACVR1C, INHBA, INHBB, INHBE, MSTN, GDF11, and DLK1.
What diseases are associated with activin receptor binding?
Dysregulation is linked to muscle wasting, obesity, cancer cachexia, and metabolic disorders.
How can I study activin receptor binding in the lab?
Common methods include surface plasmon resonance, X-ray crystallography, luciferase reporter assays, and CRISPR screens.
What is the role of ACVR2B in muscle growth?
ACVR2B is a type II activin receptor; blocking its binding with antibodies induces muscle hypertrophy.
What is DLK1 and how does it relate to activin receptor binding?
DLK1 is an endogenous inhibitor that binds to activin receptors or ligands, preventing downstream signaling.
Can CRISPR be used to study activin receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the function of activin receptors and ligands.
What is the structure of the activin receptor ligand-binding domain?
The extracellular ligand-binding domain of type II activin receptors adopts a three-finger toxin fold.
What are therapeutic strategies targeting activin receptor binding?
Monoclonal antibodies (e.g., bimagrumab) and small molecule inhibitors (e.g., SB-431542) are being developed.
How does activin E signaling differ from other activins?
Activin E signals specifically through activin receptor-like kinase 7 (ALK7), unlike other activins that may use ALK4 or ALK5.
Conclusion
Activin receptor binding (GO:0070697) is a fundamental molecular function that initiates TGF-beta superfamily signaling, with critical roles in muscle growth, metabolism, and disease. Understanding the structural and functional details of this binding event has led to promising therapeutic strategies for muscle wasting, obesity, and cancer cachexia. Continued research using advanced CRISPR models and biochemical assays will further elucidate its mechanisms and expand clinical applications.
References
- 1. Vestal KA et al.. 2024. Activin E is a transforming growth factor β ligand that signals specifically through activin receptor-like kinase 7.. Biochem J 481(7):547-564 PMID: 38533769
- 2. Abe Y et al.. 2004. Activin receptor signaling.. Growth Factors 22(2):105-10 PMID: 15253386
- 3. Kaur M et al.. 2024. Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity.. J Basic Clin Physiol Pharmacol 35(6):325-334 PMID: 39385353
- 4. Lach-Trifilieff E et al.. 2014. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy.. Mol Cell Biol 34(4):606-18 PMID: 24298022
- 5. Inman GJ et al.. 2002. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.. Mol Pharmacol 62(1):65-74 PMID: 12065756
- 6. Morvan F et al.. 2017. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.. Proc Natl Acad Sci U S A 114(47):12448-12453 PMID: 29109273
- 7. Greenwald J et al.. 1999. Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase.. Nat Struct Biol 6(1):18-22 PMID: 9886286
- 8. Antfolk D et al.. 2025. Molecular mechanism of Activin receptor inhibition by DLK1.. Nat Commun 16(1):5976 PMID: 40593645
